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Background: Periampullary adenocarcinomas comprise pancreatic, distal bile duct, ampullary and duodenal
adenocarcinoma. The epithelia of these anatomical structures share a common embryologic origin from the
foregut. With steadily increasing numbers of pancreatoduodenectomies over the last decades, pathologists,
surgeons and oncologists are more often confronted with the diagnosis of “other than pancreatic” periampullary
cancers. The intestinal subtype of ampullary cancer has been shown to correlate with better prognosis.
Methods: Histological subtype and immunohistochemical staining pattern for CK7, CK20 and CDX2 were assessed
for n = 198 cases of pancreatic ductal, distal bile duct, ampullary and duodenal adenocarcinoma with clinical follow-
up. Routine pathological parameters were included in survival analysis performed with SPSS 20.
Results: In univariate analysis, intestinal subtype was associated with better survival in ampullary, pancreatic ductal
and duodenal adenocarcinoma. The intestinal type of pancreatic ductal adenocarcinoma was not associated with
intraductal papillary mucinous neoplasm and could not be reliably diagnosed by immunohistochemical staining
pattern alone. Intestinal differentiation and lymph node ratio, but not tumor location were independent predictors
of survival when all significant predictor variables from univariate analysis (grade, TNM stage, presence of precursor
lesions, surgical margin status, perineural, vascular and lymphatic vessel invasion, CK7 and CDX2 staining pattern)
were included in a Cox proportional hazards model.
Conclusions: Intestinal type differentiation and lymph node ratio but not tumor location are independent
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The present WHO classification of tumors distinguishes
between pancreatic ductal (PDAC), extrahepatic (distal)
bile duct (DBDAC), ampullary (AMPAC) and small in-
testinal (including duodenal, DUOAC) adenocarcinoma
[1]. A fundamental observation is that survival after
resection of adenocarcinoma of periampullary location
(pancreatic head, distal bile duct, ampulla, duodenum) dif-
fers greatly, with DUOAC and AMPAC displaying a much
better survival than pancreatic head PDAC or DBDAC,
implying several issues of continued debate [2-4].
First, due to the anatomical complexity of the periam-
pullary region, correct classification with respect to loca-
tion remains challenging to the pathologist. Usually the
origin of a periampullary tumor is defined macroscopically
by location of the main tumor mass or eventual precursor
lesions and has to be confirmed microscopically [2-4].
There is still considerable debate on how localization of
adenocarcinomas and their precursor lesions arising in
this region should be assessed [2,5].
Another aspect is the question of the biological basis
of the observed differences in survival. A major step was
the recognition of the intestinal (INT) versus pancreato-
biliary (PB) histopathologic phenotypes of AMPAC by
Kimura et al. in 2004 [6]. The INT type proved to be
associated with considerably better prognosis than the
PB subtype, which has been confirmed by several recent
series [3,4,7].
Our study aimed at a detailed analysis of clinical,
pathological and immunohistochemical parameters for
assessment of tumor biology and identification of prog-
nostic factors after resection of periampullary adenocar-
cinomas of all four locations.
Methods
Patients and data
For the purpose of this study, periampullary adeno-
carcinomas were defined as pancreatic head PDAC,
DBDAC, AMPAC or DUOAC. Only cases with resection
by pancreatoduodenectomy, including conversion to
total pancreatectomy due to positive intraoperative pan-
creatic resection margin were included. Thereby cases of
the following WHO tumors [1] were excluded: PDAC
not located in the pancreatic head, solid-pseudopapillary,
acinar and neuroendocrine neoplasms, benign lesions,
pancreatoblastoma, teratoma, mesenchymal tumors,
lymphoma and secondary tumors. Patients operated at
the Clinic for General and Visceral Surgery, University
of Freiburg from 2001 to 2011 were identified and base-
line and follow-up data extracted from a prospectively
maintained database. All histopathological workup was
performed at the Insitute of Pathology, University of
Freiburg. Archived hematoxylin & eosin (H&E) stained
slides were reevaluated by two experienced pathologists(PB, IK) for accuracy of diagnosis and formalin-fixed
and paraffin-embedded tissue (FFPE) blocks were selec-
ted for generation of serial tissue slices for immuno-
histochemistry (IHC). All cases with sufficient available
FFPE for IHC were included in the study. The study
protocol was approved by the Ethics Committee of the
University of Freiburg (Ref 13/11).
Standard pathological assessment
During the study period (2001–2011), a standardized
protocol was followed for diagnostic workup of pan-
creatoduodenectomy specimens: First, resection margins
including the closest margin to the tumor and retro-
peritoneum towards portal vein and superior mesenteric
artery were marked intraoperatively by the surgeon.
After intraoperative transfer to the institute of pathology,
every specimen was examined macroscopically by an
experienced pathologist. Identifiable tumor masses or
suspect areas were measured in three dimensions.
Localization, size and distance of the tumor to the resec-
tion margins were documented and lymph node stations
were separately evaluated. After formalin fixation and
paraffin embedding, tissue slices of 3 μm thickness were
H&E stained. The following routine work up was equal
in procedure for pylorus preserving pancreatoduode-
nectomy and the classical Whipple procedure. The num-
ber of routine tissue blocks and corresponding tissue
slices was at minimum 10 (range 10 to 17). The standar-
dized protocol comprised at least two samples for the
enteral (oral and aboral) resection margins, and one
sample for each of the following locations: whole
circumferential parenchymal pancreas resection margin,
tumor in relation to the closest posterior (retroperitoneum
and vascular groove) resection margin, resection margin
at the common bile duct, tumor in relation to the com-
mon bile duct and the main duct of the pancreas, tumor
in relation to the duodenum, Papilla vateri. At minimum
twelve regional lymph nodes were embedded in at least
two routine tissue blocks. In case of portal venous en-bloc
resections, one additional tissue sample in relation to the
tumor was embedded. Additional tissue biopsies were
embedded upon request of the operating surgeon. This
standardized protocol was modified for total pancreatec-
tomy as follows. The number of routine tissue blocks and
corresponding tissue slices was minimal 11 (range 11 to
19). The resection margin of the splenic artery and vein
and one sample of the spleen were embedded additionally,
while the whole circumferential parenchymal pancreas re-
section margin was not embedded.
Histopathological reports included diagnosis according
to WHO classification, UICC stage, presence or absence
of lymphatic, vascular and perineural invasion and
assessment of oral, aboral, biliary and posterior (retroperi-
toneal and vascular groove) resection margin. Additional
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when it was felt necessary in difficult cases.
Histologic workup
For the present study, all cases were re-assessed by a
surgeon (UFW) and two experienced pathologists (PB,
IK) in terms of clinical findings and history, preexisting
macro- and histopathologic reports and H&E stained tis-
sue slides, as well as new H&E stained tissue slices to
ensure correct diagnosis according to current WHO
classification and anatomical tumor location. The site of
the main tumor mass and/or eventual precursor lesions
(intraductal papillary mucinous neoplasms of the
pancreas (IPMN) or adenomatous lesions of duodenum,
ampulla or bile duct) was used for definition. For this
study, five histological subtypes were defined. Intestinal
(INT), pancreatobiliary (PB) and mixed intestinal-
pancreatobiliary (MIX), as well as poorly differentiated
(POOR) were defined according to Albores-Saavedra
et al. [8]. An additional category was added for rare
other phenotypes (OTH), as mucinous and adenosqua-
mous adenocarcinomas were found in our collective.
According to Albores-Saavedra et al. [8], INT adenocar-
cinomas are characterized by well-formed tubular to
elongate glands, complex cribriformed areas, and solid
nests similar to colorectal adenocarcinoma, whereas PB
adenocarcinomas show simple or branching glands and
small solid nests of cells surrounded by abnormal
desmoplastic stroma (Figure 1). Few tumors with both
patterns equally distributed were assigned to the MIX
type. Poorly differentiated carcinomas (POOR) are com-
posed of solid sheets and nests admixed with densely
packed, small irregular glands and individual cells with
marked nuclear polymorphism, little or no mucin pro-
duction and strong mitotic activity (Figure 1).
Tumors containing over 50% of stromal mucin were
classified as mucinous, as proposed by the WHO clas-
sification [1] of ampullary tumors, while diagnosis of
colloid carcinoma of the pancreas requires at least 80%
of extracellular mucin pools combined with a charac-
teristic well-differentiated cuboidal to columnar cellular
morphology.
Histopathologic assessment was done by two independ-
ent pathologists blinded for the respective clinical out-
come. For classification of histopathologic subtype and
immunohistochemistry, the pathologists were blinded
towards tumor location.
Immunohistochemistry
After individual case review, tissue slides of 3 μm were
prepared from representative FFPE blocks. Immunohis-
tochemistry was carried out using commercially available
ready-to-use antibodies for cytokeratin 7 (CK7, DAKO
IR619), cytokeratin 20 (CK20, DAKO IR777), and caudaltype homeobox 2 (CDX2, DAKO IR080), LINKER
reagent (DAKO K8022) and EnVision™ Flex Visuali-
zation system (DAKO K8000) on an autostainer LINK
48 (DAKO, Hamburg, Germany) device according to the
manufacturer's instructions. The specimens were counter-
stained with hematoxylin. Omission of primary antibodies
served as negative controls and normal pancreatic and
intestinal epithelia as internal positive control.
Representative images of immunohistochemical stains
are shown in Figure 1. Immunostaining for CK7 and
CK20 was considered positive when appropriate brown
staining was seen in the tumor cell cytoplasm and
immunostaining for CDX2 when appropriate brown
staining was seen in the nucleus. CK7, CK20 and CDX2
expressions were established calculating the percent-
age of immunoreactive cells in the total number of
tumor cells and rounding to decades. Only cases with
more than 5% of positive tumor cells were regarded
as positive.
Statistics
IBM SPSS Statistics Version 20 (SPSS Inc. Chicago, IL)
was used for all statistical calculations. For exploratory
and descriptive analysis, scale variables were expressed
as median (range) and ordinal or dichotomous variables
as absolute and relative frequencies. For assessment of
diagnostic consistency, interrater reliability analysis
using the Kappa statistic was performed. Survival data
was plotted and analyzed according to the Kaplan-Meyer
method. For univariate and multivariate statistical test-
ing the following methods were used: Mann–Whitney
test, Chi squared test, Spearman rank correlation, binary
logistic regression, Logrank test and Cox regression. The
significance level was set to p = 0.05 and all statistical
tests were performed two-sided.
Results
Clinico-pathological reassessment and baseline data
From a total of 966 surgical patients assessed for eligi-
bility (Figure 2), n = 462 did not have periampullary
adenocarcinomas, n = 160 had no tumor resection and
in n = 143 cases there was insufficient tissue left for the
present study due to use for other studies. Reassessment
of clinical and pathological reports as well as histopatho-
logic reexamination of H&E stained tissue slides in 201
cases resulted in correction of data entry errors and thus
exclusion of two patients with neuroendocrine neo-
plasms and one patient with ovarian cancer metastasis
to the periampullary region. Furthermore there was a
change in diagnosis from PDAC to AMPAC in four
patients and from AMPAC to PDAC in two patients.
Follow-up survival data was complete due to regular
follow-up within the Comprehensive Cancer Center
Freiburg. Out of the 198 patients included in the study,
Figure 1 Histopathological Subtypes of Periampullary Adenocarcinomas. (a-e) hematoxylin-eosin stained tissue (H&E): (a, b)
adenocarcinoma of the pancreatobiliary type with simple branching glands lined by cuboidal columnar tumor cells with rounded nuclei and
focally cribriform growth pattern. c adenocarcinoma of the mixed type showing both intestinal and pancreatobiliary growth pattern evenly
distributed, d adenocarcinoma of the intestinal type with characteristic branching tubular glands, simple and pseudostratified mucin producing
glandular epithelium with elongated hyperchromatic and pseudostratified nuclei, (e) poorly differentiated carcinoma displaying solid insular
glandular growth pattern and remarkable nuclear atypia; (f-h) typical immunohistochemical staining patterns for cytokeratin 7 (CK7) in a
pancreatobiliary type adenocarcinoma (g), cytokeratin 20 (CK20) (f) and caudal type homeobox 2 (CDX2) (h) in an intestinal type
adenocarcinoma, pictures taken at 20-fold magnification.
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Figure 2 Flowchart of patient selection and data assessment. Abbreviations: PH-PDAC pancreatic head pancreatic ductal adenocarcinoma,
DBDAC distal bile duct adenocarcinoma, AMPAC ampullary adenocarcinoma, DUOAC duodenal adenocarcinoma.
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second largest group was ampullary cancer (n = 40),
followed by distal bile duct (n = 23) and duodenal cancer
(n = 9) (Table 1).
Clinical and baseline data are shown in Table 1. No
significant differences were found concerning age or
gender distribution among the different tumor locations.
14 patients (7%) had received neoadjuvant therapy
before resection (13 PDAC and 1 AMPAC). Distant
metastasis was very rare among resected patients (4%).
The usual resection procedure was pylorus-preserving
pancreatoduodenectomy (PPPD, n = 163), with few cases
requiring extension to classical Whipple procedure
(CWP, n = 23) or total pancreatectomy (TPE, n = 12) for
tumor invasion of the pyloric region or intraoperative
positive pancreatic resection margin, respectively. PDAC
and DBDAC were significantly more often locally
advanced as demonstrated by a higher rate of portal
venous resections (PVR) due to adhesion to or infiltra-
tion of the portal vein or it’s confluence (PDAC/DBDAC
42%/26% vs 5%/11% AMPAC/DUOAC). Perioperative
mortality was 4% (n = 7).
Basic pathology and histological subtype analysis
Results of explorative data analysis and statistical testing
concerning basic pathology are depicted in Table 1.Several statistically significant differences between the
four groups could be noted. DUOAC had the largest
median diameter (40 mm) while AMPAC (20 mm) and
DBDAC (15 mm) were smaller and PDAC intermediate
(27 mm). Only 53% of AMPAC were of stage T3 or T4,
compared to 78-87% for the other entities. Likewise,
only 8% of AMPAC had positive resection margins,
compared to 22-33% for other locations. Adenomatous
precursor lesions displayed statistically significant de-
creasing frequency from DUOAC/AMPAC (33%/30%) to
DBDAC/PDAC (17%/1%). Nine percent of PDAC were
associated with IPMN precursor lesions. High-grade
intraepithelial dysplasia was present in 17 of 20 (85%)
associated adenomatous precursor lesions and in 9 of 11
(82%) IPMN.
Results of histological subtype assessment are shown
in Table 1. The distribution of subtypes was significantly
different among the adenocarcinoma groups. The INT
type adenocarcinoma showed decreasing frequency with
distance from the duodenum in the order DUOAC –
AMPAC - DBDAC - PDAC, ranging from 56% to 9%,
while the percentage of PB type increased from 22% to
71%. Of note, two DUOAC were assigned to the PB
phenotype by application of the subtype criteria. MIX
and OTH types were not frequently encountered (0 - 9%
and 0 – 11%). The percentage of poorly differentiated
Table 1 Baseline parameters, basic pathology and immunohistochemical markers for 198 patients with periampullary
adenocarcinomas
Parameter Total PDAC DBDAC AMPAC DUOAC p
N 198 126 23 40 9 -
Male : female 102:96 63:63 14:9 22:18 3:6 0.511
Age 67 (30–89) 67 (30–89) 69 (49–83) 65 (36–84) 66 (46–78) 0.137
Distant metastasis (M1) 7 / 4% 4 / 3% 0 / 0% 2 / 5% 1 / 11% 0.448
Neoadjuvant therapy 14 / 7% 13 / 10% 0 / 0% 1 / 3% 0 / 0% 0.126
Resection PPPD 163 103 19 34 7 0.803
Whipple 23 14 2 5 2
total PE 12 9 2 1 0
PVR 62 / 31% 53 /42% 6 / 26% 2 / 5% 1 / 11% 0.000
Perioperative mortality 7 / 4% 5 / 4% 2 / 9% 0 / 0% 0 / 0% 0.300
Tumor size (mm) 25 (1–320) 27 (1–80) 15 (8–25) 20 (2–320) 40 (22–60) 0.000
Grade G3/4 72 / 37% 48 / 39% 8 / 35% 12 / 31% 4 / 44% 0.785
Stage T3/4 155 / 78% 109 / 87% 18 / 78% 21 / 53% 7 / 78% 0.000
Stage N1/2 132 / 67% 89 / 71% 14 / 61% 24 / 60% 5 / 56% 0.468
Lymph node ratio (LNR) .09 (0 - .86) .10 (0 - .86) .08 (0 - .72) .07 (0 - .71) .10 (0 - .28) 0.694
Lymphangiosis (L1) 87 / 44% 60 / 48% 5 / 22% 19 / 48% 3 / 33% 0.116
Hemangiosis (V1) 29 / 15% 22 / 18% 3 / 13% 2 / 5% 2 / 22% 0.237
Perineural invasion (Pn1) 113 / 57% 88 / 70% 12 / 52% 13 / 33% 0 / 0% 0.000
Associated precursor Adenoma 20 / 10% 1 / 1% 4 / 17% 12 / 30% 3 / 33% 0.000
IPMN 11 / 6% 11 / 9% 0 / 0% 0 / 0% 0 / 0% 0.084
Positive resection margin 51 / 26% 41 / 33% 5 / 22% 3 / 8% 2 / 22% 0.017
Subtype
INT 39 / 20% 11 / 9% 5 / 22% 18 / 45% 5 / 56% 0.000
MIX 12 / 6% 8 / 6% 2 / 9% 2 / 5% 0 / 0%
PB 118 / 16% 89 / 71% 12 / 52% 15 / 38% 2 / 22%
OTH 6 / 3% 5 / 4% 0 / 0% 0 / 0% 1 / 11%
POOR 23 / 12% 13 / 10% 4 / 17% 5 / 13% 1 / 11%
Immunohistochemical Markers
% CK7+ 90 (0–100) 90 (0–100) 95 (0–100) 80 (0–100) 0 (0–60) 0.000
% CK20+ 0 (0–100) 0 (0–100) 0 (0–100) 10 (0–100) 70 (10–100) 0.000
% nuclear CDX2+ 10 (0–100) 0 (0–100) 0 (0–100) 50 (0–100) 95 (60–100) 0.000
Values are depicted as absolute and percentage of column for categorial and median (range) for scale variables if not otherwise specified. p value derived from
two-sided Median test (scale variables), Chi squared test (categorial variables) and from two-sided Spearman rank correlation test (immunohistochemical markers),
each for the respective rows.
Abbreviations: PPPD pylorus preserving pancreatoduodenectomy, Whipple classical Whipple procedure, PE pancreatectomy, PVR portal venous resection. INT
intestinal, PB pancreatobiliary, MIX mixed intestinal-pancreatobiliary, POOR poorly differentiated carcinoma, OTH other specific subtypes, + positive, CK cytokeratin,
PDAC pancreatic ductal adenocarcinoma, DBDAC distal bile duct adenocarcinoma, AMPAC ampullary adenocarcinoma, DUOAC duodenal adenocarcinoma.
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to 17%. Rare WHO subtypes designated as OTH were
mucinous (2 PDAC and 1 DUOAC) and adenosquamous
(3 PDAC). Interrater reliability concerning the five
defined histological subtypes was found to be very good
(Kappa = 0.920, p = 0.000).
Diagnostic value of immunohistochemical markers
Results of immunohistochemical marker assessment
are presented in Table 1. Cytokeratin 7 (CK7) is a
marker of pancreatobiliary epithelia, whereas cytokeratin20 (CK20) and CDX2 are expressed by intestinal
epithelia. Median intestinal marker expression was
highest in DUOAC (CK20 and CDX2, 70% and 95%)
and decreased for AMPAC (10% and 50%) and nega-
tive for DBDAC and PDAC (median expression level
0%). The pancreatobiliary marker CK7 showed the
inverse pattern with high median expression level in
PDAC / DBDAC (90%/ 95%), decreased with AMPAC
(85%) and 0% in DUOAC. These correlations were
highly significant (p < 0.001 in two-sided Spearman
rank correlation test).
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models were used in the attempt to predict the INT
type by means of the immunohistochemical markers
CK7, CK20 and CDX2 (details shown in Table 2).
However, due to poor performance for prediction of
the INT type in PDAC / DBDAC location (0%-13%
correct prediction for univariate and 19% for multi-
variate model), even a multivariate model including
all three markers only achieved 51% correct pre-
diction for the INT type when applied to the total
patient collective.Baseline data and biology of the intestinal subtype
Results of a subgroup analysis of INT adenocarcinomas
are shown in Table 3. While median tumor size did not
differ between INT and NON-INT type (23 vs 25 mm,
p = 0.779), several attributes of lower malignant potential
could be demonstrated for INT adenocarcinomas. High
tumor grade, high T and N Stage, lymph node ratio
(LNR), perineural and vascular invasion were signifi-
cantly less frequent and expression of intestinal molecu-
lar markers CK20 and CDX2 was significantly higher
with INT versus non-INT adenocarcinoma. INT ade-
nocarcinomas were more frequently located in the
ampulla of Vater or duodenum region than in the
pancreas or distal bile duct and margin-free surgical
resection was more frequently achieved. There was a
statistically significant association of the INT type
with adenomatous precursor lesions, but not with
IPMN precursor lesions.Table 2 Diagnostic value of immunohistochemical markers fo
Location Marker % Positive t
Median (
INT
PDAC / DBDAC CK7 90 (0–100)
CK20 10 (0–100)
CDX2 45 (0–100)
CK7, CK20, CDX2 -
multivariate
AMPAC / DUOAC CK7 20 (0–100)
CK20 80 (0–100)
CDX2 90 (20–100)
CK7, CK20, CDX2 -
multivariate
ALL CK7, CK20, CDX2 -
multivariate
Prediction modeled by univariate and multivariate binary logistic regression analysi
respective row.
Abbreviations: PDAC / DBDAC / AMPAC / DUOAC pancreatic ductal/distal bile duct /
CK cytokeratin, CI confidence interval.Survival analysis for tumor location and histological subtype
Details of survival analysis regarding tumor location and
subtype are shown in Table 4 and Figure 3. Perioperative
deaths (n = 7) were excluded from survival analysis.
Overall median follow-up was 15 months (range 0–
116 months). Median survival ranged in ascending order
from 23, 29, 64 to 71 months for PDAC, DBDAC,
AMPAC to DUOAC. For histological subtypes, median
survival was 13, 22, 25 and 30 months for POOR, PB,
OTH and MIX subtype, while median survival was not
yet reached for the INT subtype. Pairwise comparison by
two-sided logrank test among histological subtypes
disclosed that significant differences existed only be-
tween INT type versus other types. Therefore, non-
intestinal types (NON-INT) were assigned to a common
group. When survival plots were stratified by tumor lo-
cation, survival after resection of INT type adenocarcin-
omas was remarkably favorable for each location,
reaching the significance level for PDAC, AMPAC and
DUOAC (Table 4 and Figure 3).
Univariate and multivariate survival analysis
Results of uni- and multivariate survival analysis are
shown in Table 5. Cases with perioperative death (n = 7)
were excluded from survival analysis. In univariate ana-
lysis, several clinicopathologic parameters were found to
be significantly associated with poor survival: necessity
of portal venous resection, high tumor grade, T stage,
N stage and LNR, lymphatic and blood vessel inva-
sionas well as positive resection margins. Presence of
a precursor lesion was significantly associated withr intestinal type adenocarcinoma
umor cells % Correct prediction p
Range)
NON-INT INT NON-INT
90 (0–100) 0% 100% 0.288
0 (0–100) 0% 100% 0.034
0 (0–90) 13% 100% 0.000
19% 100% 0.002
85 (0–100) 57% 75% 0.024
8 (0–100) 65% 79% 0.002
30 (0–100) 87% 79% 0.000
87% 75% 0.000
51% 95% 0.000
s, p values given for the two-sided overall model omnibus test of the
ampullary / duodenal adenocarcinoma, INT intestinal, NON-INT non-intestinal,
Table 3 Baseline data and biology of the intestinal subtype
Parameter INT NON-INT p
N 39 159 -
Male : female 25:14 77:82 0.079
Age 69 (36–81) 67 (30–89) 0.569
Distant metastasis (M1) 1 (3%) 6 (4%) 0.714
Neoadjuvant therapy 1 (3%) 13 (8%) 0.220
Resection PPPD 31 (80%) 132 (83%) 0.701
Whipple 6 (15%) 17 (11%)
TPE 2 (5%) 10 (6%)
PVR 8 (21%) 54 (34%) 0.105
Perioperative mortality 2 (5%) 5 (3%) 0.548
Tumor size (mm) 23 (1–320) 25 (3–70) 0.779
Grade G3/4 6 (15%) 66 (42%) 0.002
pT Stage 3/4 21 (54%) 134 (84%) 0.000
pN Stage 1/2 16 (41%) 116 (73%) 0.000
Lymph node ratio (LNR) .00 (.00-.58) .12 (.00-.86) 0.018
Lymphangiosis (L1) 12 (31%) 75 (47%) 0.064
Hemangiosis (V1) 1 (3%) 28 (18%) 0.017
Perineural invasion (Pn1) 13 (33%) 100 (63%) 0.001
Positive resection margin 3 (8%) 48 (30%) 0.004
Location PDAC / DBDAC 16 (41%) 133 (84%) 0.000
AMPAC / DUOAC 23 (59%) 26 (16%)
% CK7 85 (0–100) 90 (0–100) 0.070
% CK20 45 (0–100) 0 (0–100) 0.000
% nuclear CDX2 80 (0–100) 0 (0–100) 0.000
Associated precursor lesion Adenoma 8 (21%) 12 (8%) 0.016
IPMN 3 (8%) 8 (5%) 0.516
Values are depicted as absolute and percentage of column for categorial and median (range) for scale variables, p value derived from Mann–Whitney (scale
variables) or Chi squared test (categorial variables) for the respective row.
Abbreviations: Whipple / PPPD non / pylorus-preserving pancreatoduodenectomy, TPE total pancreatectomy, PVR portal venous resection, PDAC/DBDAC/AMPAC/
DUOAC pancreatic ductal/distal bile duct/ampullary/duodenal adenocarcinoma, NON-/INT non-/intestinal subtype, CK cytokeratin.
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adenomatous precursor lesions in non-pancreatic
adenocarcinomas (p = 0.017, two-sided Logrank test),
as the subgroup of PDAC with associated IPMN did
not show significantly better survival than PDAC
without associated IPMN (p = 0.538, Logrank test).
Both tumor location and histological subtype were
highly significant predictors of survival (p < 0.001).
Accordingly, high CK7 expression and low CDX2 ex-
pression, as characteristic of NON-INT phenotype,
were significant predictors of poor survival.
Parameters found to be significant in univariate
analysis were included in a Cox proportional hazards
model including all cases with periampullary adeno-
carcinomas (n = 191 after exclusion of n = 7 cases of
perioperative mortality). In this model, only histo-
logical subtype (Hazard Ratio 1.5, p = 0.006) and LNR
(Hazard Ratio 2.3, p = 0.019) were found to representindependent predictors of survival. This was con-
firmed by conditional backward elimination of pre-
dictive parameters.
Discussion
Only one group has so far systematically extended the
INT/PB concept to the whole spectrum of periampullary
adenocarcinomas [3,9]. We were able to validate and
extend these findings in our study. From a plethora of
prognostic markers identified in univariate analysis,
including UICC stage, tumor size, resection margin
status and even immunohistochemical markers, only
histologic subtype and lymph node ratio qualified as
independent predictors of survival. Hereby the present
study confirms that histopathological differentiation, in
contrast to tumor location, is an independent prognostic
factor. It also confirms that the lymph node ratio is a
stronger independent prognostic marker than N stage,
Table 4 Univariate survival analysis for tumor location
and histopathological subtypes in periampullary
adenocarcinomas
Location Type N Events Survival (months) p
(Deaths) Median Mean
Comparison of tumor locations versus PDAC
PDAC ALL 121 64 23 31 -
DBDAC 21 14 29 39 0.430
AMPAC 40 14 64 72 0.000
DUOAC 9 6 71 46 0.169
Comparison of tumor subtypes versus INT
ALL INT 37 8 NR 83 -
MIX 12 8 30 37 0.002
OTH WHO 6 4 25 38 0.017
PB 115 66 22 34 0.000
POOR 21 12 13 28 0.000
NON-INT 154 90 22 35 0.000
Comparison INT vs NON-INT stratified
for tumor location
PDAC NON-INT 111 63 20 29 0.034
INT 10 1 39 74
DBDAC NON-INT 17 12 12 37 0.563
INT 4 2 29 55
AMPAC NON-INT 22 11 38 56 0.019
INT 18 3 NR 90
DUOAC NON-INT 4 4 4 10 0.003
INT 5 2 75 75
Survival estimates are derived from Kaplan-Meier method, p values from two-
sided Logrank test. For Kaplan-Meier plots see Figure 3. Perioperative deaths
(n = 7) were excluded from survival analysis.
Abbreviations: INT intestinal, NON-INT non-intestinal, PB pancreatobiliary
subtype, MIX mixed subtype, POOR poorly differentiated carcinoma, OTH other
subtypes, PDAC pancreatic ductal adenocarcinoma, DBDAC distal bile duct
adenocarcinoma, AMPAC ampullary adenocarcinoma, DUOAC duodenal
adenocarcinoma, NR not reached.
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before [10,11].
We were able to demonstrate a significantly better
survival of the INT subtype not only for AMPAC but
also in the subgroups of DUOAC and PDAC, which
has not been demonstrated before due to insufficient
case numbers [3,9]. Probably due to its relatively rare
occurrence (around 10% of PDAC), INT type PDAC
has only recently been recognized [12].
The concept of INT and PB differentiation has
recently been extended to IPMN. It has been suggested
that INT type IPMN can develop into colloid carcinoma
(CAC) [13,14], which is associated with better survival
[15,16]. We show that in ampullary and duodenal loca-
tion, INT phenotype is associated with adenomatous
precursor lesions, but this is not the case in PDAC,
validating its existence as a separate entity apart fromcolloid carcinoma or invasive IPMN. In addition, one
recent study shows no association of intraductal papil-
lary neoplasms of the bile duct (IPNB) with INT type
cholangiocarcinoma [17,18]. It may therefore be sug-
gested that an “intestinal pathway” of carcinogenesis is
possible via the INT type of IPMN to colloid carcinoma,
and duodenal or ampullary adenoma to DUOAC and
AMPAC, but also without papillary precursor lesions to
INT type PDAC and DBDAC.
On the other hand, blinded application of the INT/PB
classification scheme resulted in assignment of two
DUOAC to the PB group. One might speculate that if
INT type adenocarcinoma can arise in the pancreas, vice
versa PB type adenocarcinoma may arise in rare ins-
tances in the duodenum due to common embryologic
origin, but further evaluation is currently not possible
given the exceeding rarity of DUOAC.
As CK7, CK20 and CDX2 are known to be fairly
specific markers for the discrimination of INT and PB
subtypes in AMPAC and IPMN [14,19-22], it was sur-
prising that this was not the case for PDAC and DBDAC
in our study. This finding is noteworthy as it shows that
careful morphological assessment by an experienced
pathologist outperforms immunohistochemical markers
in this respect.
This study has several limitations that have to be
mentioned. First, although data was obtained from a
prospectively maintained database, all data was ana-
lyzed retrospectively. There was a relatively high
number of cases assessed for eligibility from which
insufficient amounts of tissue were available for the
present study due to use for other studies. A selec-
tion bias by exclusion of small tumors with few tissue
can thus not totally be ruled out. Furthermore we
note a relatively high rate of PDAC in our series
compared to other recent studies [2,4] on this subject.
This may be explained in several ways: first, selection
bias excluding small tumors may favor the inclusion
of PDAC which are usually larger than AMPAC;
furthermore assignment to tumor location was not
performed according to the most recent detailed pro-
tocols [2,4] and could only be reassessed in a retro-
spective manner. Misclassification of origin especially
in large tumors cannot totally be ruled out. Neverthe-
less pathologists and surgeons at our institution since
long have been aware of this complex issue and
extensive surgical and pathological experience exists.
We believe that by primary assessment in a standar-
dized protocol as well as detailed re-assessment in
the scope of this study, risk of misclassification was
reduced to a minimum.
Another current issue concerns resection margin
status in PDAC. Some recent studies demonstrated by
extensive resection margin workup that the majority of
Figure 3 Survival plots according to histological subtypes and tumor origin. a: KM plot for all patients with periampullary adenocarcinomas,
stratified for histological subtypes. b: KM plot for all patients with periampullary adenocarcinoma, stratified for INT versus non-INT subtype. c-f: KM
plots for INT versus non-INT histological subtype divided by respective periampullary adenocarcinoma origin (pancreatic head (PDAC), ampullary
(AMPAC), distal bile duct (DBDAC), duodenal (DUOAC). perioperative deaths (n = 7) excluded, p values derived from two-sided Logrank test. For
details see also Table 4. Abbreviations: KM Kaplan Meier, INT intestinal type adenocarcinoma, PB pancreatobiliary type adenocarcinoma, MIX
mixed type adenocarcinoma, POOR poorly differentiated carcinoma, OTH other WHO types. n.s. not significant.
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[23-25]. Margin assessment in our standardized protocol
was very detailed but not as extensive as in some of theaforementioned studies, thus a number of R0 might in
fact have been R1 resections. Nevertheless our data is
validated by the fact that margin status was a prognostic
Table 5 Univariate and multivariate survival analysis for resected periampullary adenocarcinomas
Parameter Condition Median survival (months) Hazard ratio Univariate
p
Multivariate
pWith condition Without condition (95% CI)
All patients (n = 191) -26- -
Gender Male 30 25 0.953 (0.641–1.417) 0.812 NI
Age (years)1 > 67 26 27 1.050 (0.706–1.561) 0.811 NI
Distant metastasis Yes 11 27 2.044 (0.892–4.688) 0.091 NI
Neoadjuvant tx Yes 25 26 1.536 (0.741–3.182) 0.248 NI
PVR Yes 25 27 1.640 (1.068–2.517) 0.024 0.510
Tumor size (mm)1 > 25 26 26 1.069 (0.699–1.635) 0.759 NI
Tumor grade G3/4 17 31 1.808 (1.199–2.726) 0.005 0.075
pT stage pT3/4 23 41 1.938 (1.160–3.238) 0.012 0.905
pN stage pN1/2 22 52 1.883 (1.198–2.959) 0.006 0.211
LNR1 > 0.09 20 48 2.291 (1.515–3.465) 0.000 0.019
Lymphangiosis Present 22 30 1.557 (1.035–2.342) 0.033 0.398
Hemangiosis Present 12 29 1.900 (1.161–3.109) 0.011 0.384
Perineural invasion Present 25 29 1.322 (0.881–1.984) 0.177 NI
Precursor lesion Present NR 25 0.362 (0.175–0.748) 0.006 0.169
Resection margins Positive 19 37 2.368 (1.551–3.617) 0.000 0.132
Tumor subtype2 See Table 4 1.487 (1.253–1.765) 0.000 0.006
Tumor location2 See Table 4 1.471 (1.175–1.843) 0.001 0.270
CK7 + (%)1 > 90 20 38 1.757 (1.161–2.657) 0.008 0.869
CK20 + (%)1 > 0 29 23 0.311 (0.538–1.218) 0.311 NI
CDX2 + (%)1 > 10 48 20 0.562 (0.368–0.858) 0.008 0.767
Survival estimates are derived from Kaplan-Meyer method, perioperative deaths (n = 7) were excluded, univariate / multivariate p is derived from two-sided Cox
regression in a proportional hazards model.
Abbreviations: CK cytokeratin, CI confidence interval, + positive. 1 cut-off at overall median value, 2 defined as ordinal variable according to decreasing median
survival as indicated in Table 2, pos positive, tx therapy, PVR portal venous resection, NR not reached.
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within the scope of this study but will have to be
addressed in future studies.
The most important aspect of pathological diagnostic
is clinical decision making on the basis of prognostic
factors. With respect to the findings of this study, several
aspects warrant consideration.
Based on favorable survival, surgical treatment of
metastasis may be indicated in INT type AMPAC, as
already suggested by others [26]. Given the fact that
tumor location is less relevant than subtype, this concept
may be extended to PDAC, DBDAC and DUOAC. Espe-
cially since criteria for the rarely performed resection of
metastatic PDAC are poorly defined [27], subtype might
be a valuable adjunct in decision making.
Furthermore, there is still no consensus regarding the
indication and regimen for adjuvant therapy in non-
pancreatic periampullary adenocarcinomas [28-33]. In
clinical practice, treatment regimen for AMPAC,
DUOAC or DBDAC are usually extrapolated from
PDAC. Limited data suggests that patients with node
positive and margin-negative AMPAC benefit from adju-
vant therapy [28,30,33]. However, these studies did notreport on subtype. Regarding the results of our study, a
more differentiated approach based on subtype may be
suggested for future trials.
It has been shown that survival figures of series reporting
outcome of resected pancreatic head cancer have been
biased by inclusion of ampullary cancers [23,34]. In conse-
quence, more thorough examination of tumor origin has
been demanded by some authors [2]. However given the
results of our study, the biologically valid and logistically
preferable approach would be to distinguish between INT
and PB differentiation rather than tumor location. This is
emphasized by the fact that for larger tumors with involve-
ment of all periampullary structures, assessment of primary
location is very difficult or impossible.
Conclusion
In summary, our study demonstrates that histopatho-
logical subtype and lymph node ratio are the most import-
ant prognostic factors in periampullary adenocarcinomas,
outperforming all other parameters. As tumor location
becomes irrelevant with correct microscopical phenotype
classification, this may obviate the need for time-intensive
macroscopical and microscopical workup of tumor
Bronsert et al. BMC Cancer 2013, 13:428 Page 12 of 13
http://www.biomedcentral.com/1471-2407/13/428location in pancreatoduodenectomy specimen. It must be
recommended that studies and trials on outcome and
therapy of periampullary adenocarcinomas stratify for
intestinal and pancreatobiliary differentiation.
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